Duzman E, Rosen N, Lazar M
Br J Ophthalmol. 1983 Oct;67(10):668-73. doi: 10.1136/bjo.67.10.668.
In a double-masked, 3-month clinical study the ocular hypotensive effects of diacetyl nadolol (DAN), timolol, and nadolol were compared. When applied topically to the eyes of glaucomatous patients timolol 0.5% was found to be significantly more effective than DAN 2% in controlling IOP at 3 of 10 evaluation periods. Fewer patients, however, developed tolerance to DAN 2% than to timolol 0.5%. DAN 0.5% was also effective in lowering intraocular pressure in 3 of 8 patients tested. Nadolol 2% had no long-term ocular hypotensive effect. Two of 8 patients treated with DAN 2% developed a bilateral periorbital dermatitis and were removed from the study even though their intraocular pressures were well controlled. No other clinically significant local or systemic side effects were observed during the course of the study.
在一项双盲、为期3个月的临床研究中,比较了双乙酰纳多洛尔(DAN)、噻吗洛尔和纳多洛尔的降眼压效果。当局部应用于青光眼患者的眼睛时,发现在10个评估期的3个时期,0.5%的噻吗洛尔在控制眼压方面比2%的DAN显著更有效。然而,对2%的DAN产生耐受性的患者比0.5%的噻吗洛尔更少。0.5%的DAN在8名受试患者中的3名中也有效降低了眼压。2%的纳多洛尔没有长期降眼压作用。8名接受2%DAN治疗的患者中有2名出现双侧眶周皮炎,尽管他们的眼压得到了很好的控制,但仍被排除在研究之外。在研究过程中未观察到其他具有临床意义的局部或全身副作用。